Analyst Price Target Update on Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB): 4 Analyst have given the stock of Pacific Biosciences of California (NASDAQ:PACB) a near short term price target of $12. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $4.24. The higher price target estimate is at $18 while the lower price estimates are fixed at $8.

Many analysts have stated their opinion on the company shares. MKM Partners initiates coverage on Pacific Biosciences of California (NASDAQ:PACB). MKM Partners has a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $16.5 per share. The rating by the firm was issued on April 15, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Phillips James Michael, officer (SVP, Research & Development) of Pacific Biosciences Of California, Inc., had unloaded 20,000 shares at an average price of $10.29 in a transaction dated on April 25, 2016. The total value of the transaction was worth $205,800.

Pacific Biosciences of California (NASDAQ:PACB) : On Monday heightened volatility was witnessed in Pacific Biosciences of California (NASDAQ:PACB) which led to swings in the share price. The stock opened for trading at $9.8 and hit $9.88 on the upside , eventually ending the session at $9.8, with a gain of 2.51% or 0.24 points. The heightened volatility saw the trading volume jump to 1,758,056 shares. The 52-week high of the share price is $14 and the company has a market cap of $854 million. The 52-week low of the share price is at $3.58 .

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.